Colossal, founded in 2021 and headquartered in Austin, Texas, is a biotechnology company pioneering de-extinction through advanced genetic engineering and CRISPR technology. The company has raised $558 million across multiple funding rounds, reaching a $10.2 billion valuation in January 2025. With a team of 11-50 employees, Colossal focuses on reviving extinct species like the woolly mammoth, thylacine, and dodo to restore ecosystems and combat biodiversity loss. Backed by investors such as Mark Walter, Thomas Tull, and TWG Global, Colossal leads innovation in synthetic biology and conservation technology.